545 CONCORD AVENUE, CAMBRIDGE, MA
To Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Reports First Quarter 2026 Financial Results and Provides Corporate Update
To Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
Annual Report to Security Holders
Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
Financial Results, Press Release
Investor Presentation
MetaVia's GLP-1 Obesity Program Advances with IRB Approval for DA-1726 Studies
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
S-1MEF
Free Writing Prospectus
Correspondence
Submission Upload